Home > Financial Ratios > GLENMARK PHARMACEUTICALS

GLENMARK PHARMACEUTICALS
Core EBITDA Growth

    Back to All Ratios
AD     Remove this Ad

GLENMARK PHARMACEUTICALS Last 5 Year Core EBITDA Growth History

[Consolidated]

Mar2025Mar2024Mar2023Mar2022Mar2021
   Core EBITDA Growth(%) 21.125.79-22.6416.5114.91

What is the latest Core EBITDA Growth ratio of GLENMARK PHARMACEUTICALS ?

The latest Core EBITDA Growth ratio of GLENMARK PHARMACEUTICALS is 21.12 based on Mar2025 Consolidated results.
Year Core EBITDA Growth
Mar202521.12
Mar20245.79
Mar2023-22.64
Mar202216.51
Mar202114.91

How is Core EBITDA Growth of GLENMARK PHARMACEUTICALS Trending?

Years Core EBITDA Growth % Change
Mar2025 21.12
264.77
Mar2024 5.79
Positive
Mar2023 -22.64
Negative
Mar2022 16.51
10.73
Mar2021 14.91 -

Other Financial Ratios of GLENMARK PHARMACEUTICALS


Compare Core EBITDA Growth ratio of peers of GLENMARK PHARMACEUTICALS

Peers & Returns Market Capitalization 1 Week 1 Month 1 Year
GLENMARK PHARMACEUTICALS ₹58,188.2 Cr 1.6% 3% 47.9% Stock Analytics
SUN PHARMACEUTICAL INDUSTRIES ₹415,217.0 Cr 0.4% 5.6% 1.8% Stock Analytics
DIVIS LABORATORIES ₹166,047.0 Cr -0.5% 3.3% 7.9% Stock Analytics
TORRENT PHARMACEUTICALS ₹148,872.0 Cr 4.5% 10% 41.5% Stock Analytics
DR REDDYS LABORATORIES ₹108,454.0 Cr 1.5% 4.8% 9.1% Stock Analytics
CIPLA ₹107,136.0 Cr -1.7% 1% -10.5% Stock Analytics


GLENMARK PHARMACEUTICALS Share Price vs Sensex


Share Price Returns(%) 1 Week 1 Month 1 Year
GLENMARK PHARMACEUTICALS

1.6%

3%

47.9%

SENSEX

-1.5%

0.8%

8.2%


You may also like the below Video Courses